From: Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
MTX era (n = 239) | Biologic era (n = 269) | P | |
---|---|---|---|
Oligoarthritis | (n = 102) | (n = 136) | |
Patients with physician global assessment = 0 | 34/100 (34.0) | 85/134 (63.4) | < 0.0001 |
Patients with active joint count = 0 | 33/102 (32.4) | 90/136 (66.2) | < 0.0001 |
Patients with parent global assessment = 0 | 37/96 (38.5) | 61/114 (53.5) | 0.0303 |
Patients with parent pain assessment = 0 | 39/95 (41.1) | 65/122 (53.3) | 0.074 |
Patients with ID by Wallace criteria | 26/93 (28.0) | 54/94 (57.4) | < 0.0001 |
Patients with ID by JADAS10 | 24/85 (28.2) | 41/78 (52.6) | 0.0015 |
Patients with ID by cJADAS10 | 28/95 (29.5) | 63/111 (56.8) | < 0.0001 |
Patients with LDA by JADAS10 | 29/85 (34.1) | 43/78 (55.1) | 0.0070 |
Patients with LDA by cJADAS10 | 32/95 (33.7) | 64/111 (57.7) | 0.0010 |
Polyarthritis | (n = 137) | (n = 133) | |
Patients with physician global assessment = 0 | 25/132 (18.9) | 76/133 (57.1) | < 0.0001 |
Patients with active joint count = 0 | 25/136 (18.4) | 78/133 (58.6) | < 0.0001 |
Patients with parent global assessment = 0 | 33/127 (26.0) | 53/113 (46.9) | 0.0007 |
Patients with parent pain assessment = 0 | 38/125 (30.4) | 58/118 (49.2) | 0.0028 |
Patients with ID by Wallace criteria | 19/129 (14.7) | 48/98 (49.0) | < 0.0001 |
Patients with ID by JADAS10 | 19/115 (16.5) | 34/84 (40.5) | 0.0002 |
Patients with ID by cJADAS10 | 21/122 (17.2) | 54/112 (48.2) | < 0.0001 |
Patients with LDA by JADAS10 | 33/115 (28.7) | 52/84 (61.9) | < 0.0001 |
Patients with LDA by cJADAS10 | 29/122 (23.8) | 60/112 (53.6) | < 0.0001 |